Previous close | 303.78 |
Open | 304.56 |
Bid | 301.02 x 1000 |
Ask | 309.50 x 1400 |
Day's range | 300.75 - 306.40 |
52-week range | 225.28 - 325.19 |
Volume | |
Avg. volume | 1,444,326 |
Market cap | 77.269B |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | 24.22 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BOSTON, January 17, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call".
BOSTON, January 04, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.
BOSTON, December 12, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex plans to initiate a sin